Published: October 6, 2025 at 8:21 am
Edinburgh-based MedTech Trogenix has raised £70 million in a Series A funding round to accelerate the development of its next-generation cancer therapies targeting aggressive solid tumours.
The investment, led by IQ Capital, will enable the company to advance its lead programme in glioblastoma and a follow-on programme in colorectal cancer liver metastases.
It will also help the firm to expand its pipeline in liver and lung cancers, as well as support the continued development of its proprietary Odysseus platform.
The business, founded just two years ago, has built the platform to identify and target the universal vulnerabilities of solid tumours.